Mitochondrial dysfunction and oxidative damage in Alzheimer’s and Parkinson’s diseases and coenzyme Q10 as a potential treatment

Author(s): Beal MF

Abstract

There is substantial evidence that mitochondrial dysfunction and oxidative damage may play a key role in the pathogenesis of neurodegenerative disease. Evidence supporting this in both Alzheimer's and Parkinson's diseases is continuing to accumulate. This review discusses the increasing evidence for a role of both mitochondrial dysfunction and oxidative damage in contributing to beta-amyloid deposition in Alzheimer's disease. I also discuss the increasing evidence that Parkinson's disease is associated with abnormalities in the electron transport gene as well as oxidative damage. Lastly, I reviewed the potential efficacy of coenzyme Q as well as a number of other antioxidants in the treatment of both Parkinson's and Alzheimer's diseases.

Similar Articles

Coenzyme Q10 for heart failure

Author(s): Madmani M, Yusuf Solaiman A, Tamr Agha K, Madmani Y, Shahrour Y, et al.

D-Ribose aids congestive heart failure patients

Author(s): Omran H, St Cyr J, Lüderitz B

Vigilanz, Einschlafneigung, Daueraufmerksamkeit, Müdigkeit, Schläfrigkeit

Author(s): Weeß HG, Lund R, Gresele C, Böhning W, Sauter C, et al.

Relative Bioavailability of coenzyme Q10 formulations in human subjects

Author(s): Chopra RK, Goldman R, Sinatra ST, Bhagavan HN

Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers

Author(s): Weis M, Mortensen SA, Rassing MR, Møller-Sonnergaard J, Poulsen G, et al.

Comparison of the relative bioavailability of different coenzyme Q10 formulations with a novel solubilizate (Solu Q10)

Author(s): Schulz C, Obermüller-Jevic UC, Hasselwander O, Bernhardt J, Biesalski HK